PE-22-28 (Spadin Analog)
Also known as PE-22-28 · Spadin analog · TREK-1 inhibitor peptide
New
Reconstitution & dosing guide
10 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
PE-22-28 · Not in current stock
$25 / vial
Prices per vial · Research use only · Not medical advice.
Synthetic heptapeptide optimized from the natural sortilin-derived peptide spadin. Potent selective inhibitor of the TREK-1 (KCNK2) two-pore-domain potassium channel with preclinical antidepressant and neuroplasticity signals.
How to picture it
Neurons have background "leak" channels that let potassium slip out, which makes the cell more settled and harder to fire. TREK-1 is one of those calming leak channels. PE-22-28 is a potent blocker of TREK-1 — picture partially closing a pressure-relief valve so certain circuits (including mood-related ones in research) can regain dynamic range instead of staying stuck too quiet. Adjusting a neuron's idle valve, not flooding the brain with a broad stimulant.
Research focus & benefits
- TREK-1 potassium-channel research
- Mood and resilience circuit interest
- Selective neuronal excitability studies
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
PE-22-28 is a shortened, optimized analog of spadin (the PE 12–28 fragment released during sortilin maturation). Developed by French labs studying TREK-1 as an antidepressant target, it shows sub-nanomolar channel block and rapid behavioral effects in rodents. Human clinical data are essentially absent; it remains an early-stage research tool popular in nootropic catalogs.
Mechanism
Selectively blocks TREK-1 (KCNK2) with reported IC50 near 0.12 nM — roughly 300-fold more potent than parent spadin. TREK-1 blockade increases excitability of dorsal-raphe serotonergic neurons, elevates BDNF, phosphorylates CREB, and induces hippocampal neurogenesis within ~4 days in mouse models. Duration of antidepressant-like behavior reported up to ~23 hours in key characterization work.
Research uses
- TREK-1 channel pharmacology
- Rapid-onset antidepressant models (forced swim, novelty-suppressed feeding)
- Hippocampal neurogenesis and BDNF upregulation
- Serotonergic circuit research
Research dosing notes
Preclinical work uses microgram-range systemic dosing. Community research vials are typically 5–10 mg. No validated human dose exists.
Half-life / kinetics
Short plasma; behavioral effects longer in rodents (~hours to a day)
Common research routes
Reported considerations
- Unknown human adverse-effect profile
- Theoretical cardiac TREK-1 expression concerns uncharacterized for this peptide
- Injection or nasal irritation
Contraindications / cautions
- Pregnancy
- Active serious psychiatric illness requiring standard care
- Unsupervised use as antidepressant substitute
Common research stacks
- Semax
- Selank
- P21
- DSIP
Legal / access note
Research chemical; not an approved antidepressant or nootropic drug.